Financial Instruments and Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2026

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

			Fair Value Measurement Using Fair Value Hierarchy:
	March 31, 2026		Level 1		Level 2		Level 3
Assets:
Equity securities	$	4.3	$	4.3	$	—	$	—
	$	4.3	$	4.3	$	—	$	—
Liabilities:
Deferred compensation liabilities	$	19.8	$	—	$	19.8	$	—
Contingent consideration liabilities	55.4		—		—		55.4
	$	75.2	$	—	$	19.8	$	55.4

			Fair Value Measurement Using Fair Value Hierarchy:
	December 31, 2025		Level 1		Level 2		Level 3
Assets:
Equity securities	$	10.5	$	10.5	$	—	$	—
	$	10.5	$	10.5	$	—	$	—
Liabilities:
Deferred compensation liabilities	$	21.7	$	—	$	21.7	$	—
Contingent consideration liabilities	54.8		—		—		54.8
	$	76.5	$	—	$	21.7	$	54.8

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table summarizes activity for contingent consideration:

	Terlivaz CVR (1)		Edex (2)		Total
December 31, 2025	$	20.0	$	34.8	$	54.8
Fair value adjustment	—		0.6		0.6
March 31, 2026	$	20.0	$	35.4	$	55.4

(1) Fair value classified within accrued and other liabilities as of March 31, 2026 and December 31, 2025.

(2) Includes fair value of $3.0 million as of March 31, 2026 and December 31, 2025 classified within accrued and other current liabilities, respectively.

Schedule of Carrying Amount and Fair Value of Long-Term Debt

	March 31, 2026				December 31, 2025
	Carrying Value		Fair Value		Carrying Value		Fair Value
Level 1:
8.50% Senior Secured Notes due April 2031	$	1,057.1	$	1,048.0	$	1,060.0	$	1,058.1
Level 2:
Term Loan due April 2031	1,483.3		1,471.0		1,487.3		1,472.0
Total Debt	$	2,540.4	$	2,519.0	$	2,547.3	$	2,530.1

Schedules of Concentration of Risk

The following table shows net sales attributable to customers that accounted for 10.0% or more of the Company's total net sales:

	Three Months Ended
	March 31, 2026		March 28, 2025
FFF Enterprises, Inc.	34.4	%	54.8	%
Cencora, Inc.	19.8		*
CVS Health Corporation	12.3		*

* Net sales to this customer were less than 10.0% of total net sales during the respective periods presented above.

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:

	March 31, 2026		December 31, 2025
Cencora, Inc.	36.3	%	47.5	%
FFF Enterprises, Inc.	30.8		19.2